The Recall Desk
HighFDA (Devices)·Z-0155-2024·Announced 2023-11-01

SOZO Bilateral Arm L-Dex Software inadequate lymphedema detection sensitivity

Impedimed's SOZO Bilateral Arm L-Dex Software (versions 4.1 and 5.0) has inadequate sensitivity for detecting early lymphedema, which could delay treatment. The FDA is recalling 354 units distributed nationwide.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: This Class II medical device recall involves inadequate diagnostic sensitivity that could result in under-recognition of lymphedema and delayed treatment. As no illnesses or injuries have been reported and the potential harm is theoretical, the severity is rated as High per the rubric.

Plain-English summary

The FDA has recalled the SOZO Bilateral Arm L-Dex Software (versions 4.1 and 5.0), manufactured by Impedimed Limited. The recall affects 354 units distributed nationwide across 43 states and Washington, DC.

The bilateral L-Dex assessment software has reduced sensitivity compared to the unilateral arm L-Dex assessment for detecting early lymphedema. This lower sensitivity could result in under-recognition of early lymphedema, which could lead to delayed early intervention and require more aggressive treatment later.

Healthcare facilities and providers using this software should contact Impedimed Limited for guidance regarding available remediation measures or software updates. For additional information about this recall, refer to the FDA's official recall notice.

The recalled product

Product
SOZO Bilateral Arm L-Dex Software
Manufacturer
Impedimed Limited
Hazard
  • inadequate-sensitivity
  • misdiagnosis
  • delayed-treatment

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (1)

  • UDI-DI: B277SFT0250. Software v4.1 and v5.0

Distribution

Distributed nationwide across the United States.